PEAK1

Across TCGA pan-cancer cohorts, PEAK1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PEAK1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PEAK1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PEAK1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and ESCA are the cancer types where PEAK1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	IV	0.106	0.791	<.001	14	view →
UCEC	DFS	Median	All	0.947	0.825	.015	14	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PEAK1–BRCA (OS)

Open the BRCA breakdown →